Using exomes and linked electronic health records, the team uncovered a loss-of-function variant associated with decreased risk of liver disease and cirrhosis.
Using small RNA sequencing, investigators found miRNAs in the blood that track with cirrhosis, hepatitis, type 2 diabetes, or acetaminophen toxicity.
Called the Glyco Liver Profile, the test uses capillary electrophoresis to measure glycosylation of proteins to diagnosis and monitor chronic liver diseases.
The partners will develop biomarkers and assays to evaluate non-alcoholic steatohepatitis, a disease characterized by liver scarring due to inflammation.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
Researchers sequenced and analyzed the negative-sense RNA tilapia lake virus, implicated in large die-offs of farmed and wild tilapia in Israel and Ecuador.
In Nature this week: DNA-free genome editing in plants, new risk loci for atopic dermatitis, and more.
A two-stage genome-wide association study has linked new loci to alcohol-related cirrhosis risk and confirmed a previously identified one.
A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.
A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.
Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.
In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.